Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.71 |
| ▸ | CDK2 | P24941 | 20/20 | 0.71 |
| ▸ | KDR | P35968 | 18/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.65 |
| ▸ | CDK4 | P11802 | 3/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.46 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989325 | 0.89 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4580255 | 0.86 | CDK1 (0.74) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3988093 | 0.85 | CDK1 (0.67) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14112842 | 0.85 | CDK1 (0.78) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3931191 | 0.83 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14140889 | 0.83 | CDK1 (0.75) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3984788 | 0.82 | CDK1 (0.60) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3989327 | 0.81 | CDK1 (0.67) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3984442 | 0.81 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3929323 | 0.81 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059511-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | CDK1 6/4885CDK2 4/4885KDR 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.